Ethics body approves another clinical trial using MGC Pharma’s epilepsy drug

Special Report: MGC Pharma’s flagship epilepsy drug CannEpil will be the subject of yet another clinical trial after Australia’s ethics body approved a new study. MGC (ASX:MXC) will conduct a head-to-head clinical study on severe intractable epilepsy in collaboration with Cannabis Access Clinics and Epilepsy Action Australia, a direct comparison assessing the efficacy of low-THC … Continue reading Ethics body approves another clinical trial using MGC Pharma’s epilepsy drug

Stockhead

Hear it first

Get the latest Stockhead news delivered free to your inbox.

Email Lists

Thanks! You’re subscribed, Stockhead news is coming your way soon.